51 results
424B3
BTTX
Better Therapeutics Inc
28 Dec 23
Prospectus supplement
9:23pm
their development, assessment and review, while preserving the statutory standards for premarket approval, 510(k) clearance and de novo marketing … with the SEC rules that implement Section 404 of the Sarbanes-Oxley Act and are therefore not required to make a formal assessment of the effectiveness
8-K
EX-10.1
1ylmhwt s0
13 Dec 23
Entry into a Material Definitive Agreement
5:06pm
8-K
EX-10.1
ymf3kvnpsdjyr6cq
11 May 23
Entry into a Material Definitive Agreement
5:23pm
S-3
EX-4.10
h6g 6acrur5
17 Apr 23
Shelf registration
5:48pm
S-3
EX-4.9
v2sj5b
17 Apr 23
Shelf registration
5:48pm
8-K
EX-99.2
o92x g5gkcfseo1
9 Dec 22
Better Therapeutics Completes Exploratory Trial for Fatty Liver Disease and Announces Positive Topline Results
6:56pm
424B3
mkbf4
15 Nov 22
Prospectus supplement
9:56pm